NK

Please, somebody help me make sure I understand this correctly.

Regarding:

"Ownership of the Combined Company after the Merger (See page 154)
Based on the exchange ratio of 0.8190, on a fully diluted basis, NantKwest stockholders as of immediately prior to the merger will hold, in the aggregate, approximately 28% of the outstanding shares of common stock of the combined company immediately following the merger, and ImmunityBio stockholders as of immediately prior to the merger will hold, in the aggregate, approximately 72% of the outstanding shares of common stock of the combined company immediately following the merger."

I have 10,000 shares. 10,000 x 28%= 2,800 shares after merger.
Let's say NK price per share before merger is $20. 10,000 x 20= $200,000.

So, if all things were fair & equal, price per share of newly merger company would have to be $71.43 for me to retain the same dollar amount of value after merger. 2800 x $71.43 = $200,004.

Am I correct in all that?

Don’t worry, long fuse on good news. Shorts will find a new shiny red ball to play with and NK will pop

@Steve Butt
?
lol

I'm not sure we can know how much value we NK shareholders are going to get or not. The dilution concerns me. I'm no Wall Street wolf. Anybody have an educated opinion on the value & dilution aspects of the merger?

@ Gary Carter

No, as I understand it, you won't have your original number of 1000 shares after the merger. This is all we know, according to NK & ImmunityBio release on their websites:

ImmunityBio shareholders will receive a fixed exchange ratio of 0.8190 shares of NantKwest for each share of ImmunityBio owned. Upon completion of the transaction, on a fully diluted basis, ImmunityBio shareholders will own approximately 72% of the combined company and NantKwest shareholders will own approximately 28% of the combined company, on a fully diluted basis.

?.......

There’s only 40million float on this come on we’re almost there

?
go baby go!
In NK deep & long, since ipo

Following the closing of the transaction, the combined company will assume the ImmunityBio name and continue to be listed on the NASDAQ exchange. However, the combined company ticker symbol is expected to be changed to IBRX.

Following the closing of the transaction, the combined company will assume the ImmunityBio name and continue to be listed on the NASDAQ exchange. However, the combined company ticker symbol is expected to be changed to IBRX.